Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1978 1
1987 1
1988 3
1992 2
1993 1
1995 2
2005 1
2008 1
2009 1
2010 5
2012 1
2013 2
2014 3
2015 1
2016 1
2017 1
2018 2
2021 0
Text availability
Article attribute
Article type
Publication date

Search Results

27 results
Results by year
Filters applied: . Clear all
Page 1
Monoclonal antibodies against doxorubicin.
Balsari A, Alzani R, Parrello D, Morelli D, Tagliabue E, Gianni L, Isetta AM, Menard S, Colnaghi MI, Ghione M. Balsari A, et al. Among authors: alzani r. Int J Cancer. 1988 Nov 15;42(5):798-802. doi: 10.1002/ijc.2910420528. Int J Cancer. 1988. PMID: 3182109
Phosphorylation of TCTP as a marker for polo-like kinase-1 activity in vivo.
Cucchi U, Gianellini LM, De Ponti A, Sola F, Alzani R, Patton V, Pezzoni A, Troiani S, Saccardo MB, Rizzi S, Giorgini ML, Cappella P, Beria I, Valsasina B. Cucchi U, et al. Among authors: alzani r. Anticancer Res. 2010 Dec;30(12):4973-85. Anticancer Res. 2010. PMID: 21187478
Optimization of 6,6-dimethyl pyrrolo[3,4-c]pyrazoles: Identification of PHA-793887, a potent CDK inhibitor suitable for intravenous dosing.
Brasca MG, Albanese C, Alzani R, Amici R, Avanzi N, Ballinari D, Bischoff J, Borghi D, Casale E, Croci V, Fiorentini F, Isacchi A, Mercurio C, Nesi M, Orsini P, Pastori W, Pesenti E, Pevarello P, Roussel P, Varasi M, Volpi D, Vulpetti A, Ciomei M. Brasca MG, et al. Among authors: alzani r. Bioorg Med Chem. 2010 Mar 1;18(5):1844-53. doi: 10.1016/j.bmc.2010.01.042. Epub 2010 Jan 25. Bioorg Med Chem. 2010. PMID: 20153204
A novel method using blinatumomab for efficient, clinical-grade expansion of polyclonal T cells for adoptive immunotherapy.
Golay J, D'Amico A, Borleri G, Bonzi M, Valgardsdottir R, Alzani R, Cribioli S, Albanese C, Pesenti E, Finazzi MC, Quaresmini G, Nagorsen D, Introna M, Rambaldi A. Golay J, et al. Among authors: alzani r. J Immunol. 2014 Nov 1;193(9):4739-47. doi: 10.4049/jimmunol.1401550. Epub 2014 Sep 29. J Immunol. 2014. PMID: 25267972 Free article.
A Cdc7 kinase inhibitor restricts initiation of DNA replication and has antitumor activity.
Montagnoli A, Valsasina B, Croci V, Menichincheri M, Rainoldi S, Marchesi V, Tibolla M, Tenca P, Brotherton D, Albanese C, Patton V, Alzani R, Ciavolella A, Sola F, Molinari A, Volpi D, Avanzi N, Fiorentini F, Cattoni M, Healy S, Ballinari D, Pesenti E, Isacchi A, Moll J, Bensimon A, Vanotti E, Santocanale C. Montagnoli A, et al. Among authors: alzani r. Nat Chem Biol. 2008 Jun;4(6):357-65. doi: 10.1038/nchembio.90. Epub 2008 May 11. Nat Chem Biol. 2008. PMID: 18469809
Phase I dose escalation study of NMS-1286937, an orally available Polo-Like Kinase 1 inhibitor, in patients with advanced or metastatic solid tumors.
Weiss GJ, Jameson G, Von Hoff DD, Valsasina B, Davite C, Di Giulio C, Fiorentini F, Alzani R, Carpinelli P, Di Sanzo A, Galvani A, Isacchi A, Ramanathan RK. Weiss GJ, et al. Among authors: alzani r. Invest New Drugs. 2018 Feb;36(1):85-95. doi: 10.1007/s10637-017-0491-7. Epub 2017 Jul 20. Invest New Drugs. 2018. PMID: 28726132 Clinical Trial.
27 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page